ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer

Maintenance treatment in multiple myeloma: A new era

Preclinical models for small-cell lung cancer

Conducting Oncology Clinical Trials in Africa II: Regulatory Process for Clinical Trials in Africa

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Conducting Oncology Clinical Trials in Africa II: Twitter Workshop

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma